Tag: reninangiotensinsystem rasacting agents market analysis

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Renin-Angiotensin-System (RAS)-Acting Agents Market Value Expansion And Long-Term Growth Outlook

The renin-angiotensin-system (RAS)-acting agents market has experienced robust expansion in recent years, with its value projected to rise from $6.11 billion in 2025 to $6.44 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.5%. This historical growth is driven by factors such as the high incidence of hypertension, an expanding elderly demographic, the widespread uptake of ACE inhibitors, enhanced cardiovascular screening programs, and the cost-effectiveness of generic medications.

Forecasts indicate robust expansion within the renin-angiotensin-system (RAS)-acting agents market over the coming years. By 2030, its value is projected to reach $7.96 billion, representing a compound annual growth rate (CAGR) of 5.4%. Several key factors are expected to drive this growth during the forecast period, including the rising burden of chronic kidney disease, heightened demand for cardiometabolic medications, better rates of treatment adherence, growing opportunities in emerging markets, and approvals for combination therapies. Among the significant developments shaping this period are the increased adoption of combination antihypertensive treatments, the development of long-acting cardiovascular therapies, a growing emphasis on renal protection strategies, the rising availability of generic RAS drugs, and a noticeable movement toward fixed-dose combinations.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23496&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Renin-Angiotensin-System (RAS)-Acting Agents Market Growth Factors Supporting Long-Term Expansion

The growing incidence of hypertension is anticipated to accelerate the expansion of the renin-angiotensin system (RAS)-acting agents market. Hypertension, commonly known as high blood pressure, is a chronic condition characterized by persistently elevated force of blood against artery walls. Its rising prevalence stems largely from unhealthy dietary patterns, particularly those rich in salt and processed foods, which elevate blood pressure and add stress to the cardiovascular system. By blocking angiotensin II—a hormone that narrows blood vessels and promotes fluid retention—renin-angiotensin system (RAS)-acting agents help regulate blood pressure, facilitating vasodilation and reducing hypertension rates. As an example, in September 2025, the World Health Organization, an intergovernmental organization based in Switzerland, reported that an estimated 1.4 billion adults aged 30–79 worldwide were living with hypertension in 2024, accounting for roughly 33% of that age group. Hence, the escalating prevalence of hypertension is fueling growth in the renin-angiotensin system (RAS)-acting agents market.

Renin-Angiotensin-System (RAS)-Acting Agents Market Segment Landscape: Which Areas Lead Market Development?

The renin-angiotensin-system (ras)-acting agents market covered in this report is segmented –

1) By Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Renin Inhibitors, Aldosterone Antagonists, Other Drug Classes

2) By Indication: Hypertension, Heart Failure, Chronic Kidney Disease, Diabetic Nephropathy, Coronary Artery Disease

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics

4) By End-User: Hospitals, Research Institutes, Pharmaceutical Companies, Other End-Users

Subsegments:

1) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Captopril, Enalapril, Lisinopril, Ramipril, Perindopril

2) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan, Olmesartan, Telmisartan

3) By Renin Inhibitors: Aliskiren

4) By Aldosterone Antagonists: Spironolactone, Eplerenone

5) By Other Drug Classes: Dual Angiotensin Receptor-Neprilysin Inhibitors (ARNIs), Vasopeptidase Inhibitors, Mineralocorticoid Receptor Antagonists (MRAs), Angiotensin Receptor Blockers With Neprilysin Inhibitors (ARNBIs)

Renin-Angiotensin-System (RAS)-Acting Agents Market Industry Trends Shaping Future Revenue Growth

Major pharmaceutical companies in the renin-angiotensin system (RAS)-acting agents market are concentrating their efforts on creating innovative RAS inhibitors, particularly angiotensin-converting enzyme (ACE) inhibitors, with the aim of improving effectiveness, reducing adverse effects, increasing patient adherence, and addressing conditions like hypertension, heart failure, and kidney disorders. An ACE inhibitor functions as a pharmaceutical agent that reduces blood pressure by inhibiting the enzyme responsible for converting angiotensin I into angiotensin II, a compound known to constrict blood vessels. A case in point occurred in November 2023, when Proveca Ltd., a pharmaceutical firm headquartered in the UK, was granted a pediatric use marketing authorization (PUMA) by the European Commission for Aqumeldi (enalapril maleate) orodispersible tablets. These tablets are specifically indicated for managing heart failure in children ranging from birth to under 18 years of age. Aqumeldi works as an ACE inhibitor, providing treatment for pediatric heart failure patients by blocking the action of ACE, which prevents the transformation of angiotensin I to angiotensin II. This mechanism leads to the relaxation of blood vessels, enhanced blood circulation, and a reduction in the heart’s workload.

Renin-Angiotensin-System (RAS)-Acting Agents Market Industry Leaders And Market Competition

Major companies operating in the renin-angiotensin-system (ras)-acting agents market are Novartis AG, AstraZeneca plc, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Pfizer Inc., Sanofi S.A., Bayer AG, Daiichi Sankyo Company Limited, Astellas Pharma Inc., Biocon Limited, Lupin Limited, Sun Pharmaceutical Industries Ltd., Mylan N.V., Zydus Lifesciences Limited

Access The Complete Renin-Angiotensin-System (RAS)-Acting Agents Market Report:

https://www.thebusinessresearchcompany.com/report/renin-angiotensin-system-ras-acting-agents-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Renin-Angiotensin-System (RAS)-Acting Agents Market Regional Analysis And Leading Geography

North America was the largest region in the renin-angiotensin-system (RAS)-acting agents market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the renin-angiotensin-system (ras)-acting agents market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Expected Market Size Of The Renin-Angiotensin-System (RAS)-Acting Agents Market In 2026 And How Much Will It Reach By 2030?

Recent years have seen robust growth in the renin-angiotensin-system (ras)-acting agents market size. It is projected to expand from $6.11 billion in 2025 to $6.44 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.5%. The expansion historically can be ascribed to high hypertension prevalence, aging population growth, widespread ACE inhibitor adoption, increased cardiovascular screening, and the affordability of generic drugs.

The renin-angiotensin-system (ras)-acting agents market size is projected to experience robust expansion over the coming years. This market is set to reach $7.96 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 5.4%. This anticipated growth during the forecast period is primarily driven by factors such as the prevalence of chronic kidney disease, increasing demand for cardiometabolic medications, enhanced patient adherence to treatments, market expansion into developing regions, and the approval of combination therapies. Key trends influencing the market in this period encompass a rise in the adoption of combination antihypertensive therapies, the development of long-acting cardiovascular drugs, a heightened emphasis on renal protection treatments, the broader production of generic RAS drugs, and a move towards fixed-dose combination formulations.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23496&type=smp

What Primary Factors Are Fueling The Expansion Of The Renin-Angiotensin-System (RAS)-Acting Agents Market?

The increasing prevalence of hypertension is expected to propel the growth of the renin-angiotensin system (RAS)-acting agents market going forward. Hypertension, also known as high blood pressure, is a chronic medical condition characterized by persistently excessive force of blood against artery walls. This rise in hypertension prevalence is attributed to unhealthy diets, especially those high in salt and processed foods, which contribute to elevated blood pressure and strain on the cardiovascular system. Renin-angiotensin system (RAS)-acting agents work to lower hypertension rates by regulating blood pressure. They do this by inhibiting angiotensin II, a hormone that constricts blood vessels and promotes fluid retention, thereby encouraging vasodilation and reducing blood pressure. For instance, in September 2025, the World Health Organization, a Switzerland-based intergovernmental organization, estimated that 1.4 billion adults worldwide aged 30–79 were living with hypertension in 2024, constituting about 33% of individuals in this age group. Therefore, the increasing prevalence of hypertension is driving the growth of the renin-angiotensin system (RAS)-acting agents market.

Which Segment Divisions Form The Structure Of The Renin-Angiotensin-System (RAS)-Acting Agents Market?

The renin-angiotensin-system (ras)-acting agents market covered in this report is segmented –

1) By Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Renin Inhibitors, Aldosterone Antagonists, Other Drug Classes

2) By Indication: Hypertension, Heart Failure, Chronic Kidney Disease, Diabetic Nephropathy, Coronary Artery Disease

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics

4) By End-User: Hospitals, Research Institutes, Pharmaceutical Companies, Other End-Users

Subsegments:

1) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Captopril, Enalapril, Lisinopril, Ramipril, Perindopril

2) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan, Olmesartan, Telmisartan

3) By Renin Inhibitors: Aliskiren

4) By Aldosterone Antagonists: Spironolactone, Eplerenone

5) By Other Drug Classes: Dual Angiotensin Receptor-Neprilysin Inhibitors (ARNIs), Vasopeptidase Inhibitors, Mineralocorticoid Receptor Antagonists (MRAs), Angiotensin Receptor Blockers With Neprilysin Inhibitors (ARNBIs)

What Trends Are Affecting The Growth Of The Renin-Angiotensin-System (RAS)-Acting Agents Market?

Leading firms within the renin-angiotensin system (RAS)-acting agents sector are concentrating on creating innovative renin-angiotensin system (RAS) inhibitors, including angiotensin-converting enzyme (ACE) inhibitors. This development aims to boost effectiveness, reduce adverse reactions, increase patient adherence, and address conditions such as high blood pressure, cardiac insufficiency, and renal disorders. An angiotensin-converting enzyme (ACE) inhibitor functions as a drug designed to lower blood pressure by inhibiting the enzyme responsible for transforming angiotensin I into angiotensin II, a compound known to constrict blood vessels. As an illustration, in November 2023, Proveca Ltd., a pharmaceutical company based in the UK, was awarded a grant by the European Commission. This grant was for pediatric use marketing authorization (PUMA) for its Aqumeldi (enalapril maleate) orodispersible tablets, prescribed for managing heart failure in children from birth up to 18 years of age. Aqumeldi, an angiotensin-converting enzyme (ACE) inhibitor, addresses pediatric heart failure by inhibiting the angiotensin-converting enzyme (ACE). This action prevents the transformation of angiotensin I into angiotensin II, leading to blood vessel relaxation, enhanced blood circulation, and a reduced strain on the heart.

Who Are The Leading Firms Participating In The Renin-Angiotensin-System (RAS)-Acting Agents Market?

Major companies operating in the renin-angiotensin-system (ras)-acting agents market are Novartis AG, AstraZeneca plc, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Pfizer Inc., Sanofi S.A., Bayer AG, Daiichi Sankyo Company Limited, Astellas Pharma Inc., Biocon Limited, Lupin Limited, Sun Pharmaceutical Industries Ltd., Mylan N.V., Zydus Lifesciences Limited

Access The Complete Renin-Angiotensin-System (RAS)-Acting Agents Market Report:

https://www.thebusinessresearchcompany.com/report/renin-angiotensin-system-ras-acting-agents-global-market-report

Which Regional Market Leads The Renin-Angiotensin-System (RAS)-Acting Agents Market?

North America was the largest region in the renin-angiotensin-system (RAS)-acting agents market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the renin-angiotensin-system (ras)-acting agents market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Renin-Angiotensin-System (RAS)-Acting Agents Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=23496&type=smp

Browse Through More Reports Similar to the Global Renin-Angiotensin-System (RAS)-Acting Agents Market 2026, By The Business Research Company

Angiotensin Receptor Blockers Arbs Market Report 2026

https://www.thebusinessresearchcompany.com/report/angiotensin-receptor-blockers-arbs-global-market-report

Angina Pectoris Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report

Inotropic Agents Market Report 2026

https://www.thebusinessresearchcompany.com/report/inotropic-agents-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the biguanides market from 2025–2034 with trusted insights from The Business Research Company

What Is The Current Size And Expected Growth Outlook For The Biguanides Market?

The market size for renin-angiotensin-system (RAS)-acting agents has experienced steady expansion in recent years. It is anticipated to increase from $5.82 billion in 2024 to $6.11 billion in 2025, reflecting a compound annual growth rate (CAGR) of 5.0%. This growth observed historically can be attributed to several factors, including the rising prevalence of hypertension, a growing incidence of cardiovascular diseases, an expanding aging population, enhanced awareness concerning blood pressure management, robust clinical research support, and the regulatory approvals for new drugs.

The market size for renin-angiotensin-system (RAS)-acting agents is anticipated to demonstrate significant growth in the upcoming years. It is projected to expand to $7.55 billion by 2029, achieving a compound annual growth rate (CAGR) of 5.4%. The expansion during the forecast period is attributable to an increased focus on personalized treatment, a rising need for fixed-dose combinations, heightened investment in cardiovascular research, greater healthcare accessibility in emerging markets, and a growing prevalence of lifestyle-related diseases. Significant trends expected in this period include artificial intelligence (AI)-driven drug development, nanotechnology-based drug delivery, advancements in personalized medicine, blockchain for secure clinical data management, wearable biosensors for hypertension monitoring, and the use of digital twin technology for patient modeling.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23496&type=smp

Which Growth Drivers Are Propelling The Biguanides Market?

The rising incidence of hypertension is projected to boost the expansion of the renin-angiotensin system (RAS)-acting agents market moving ahead. Hypertension, also known as elevated blood pressure, represents an ongoing medical state where the pressure of blood against arterial walls remains persistently excessive. The increase in hypertension cases stems from poor dietary choices, especially foods rich in salt and processed ingredients, leading to heightened blood pressure and stress on the heart and blood vessels. Renin-angiotensin system (RAS)-acting agents contribute to lessening hypertension by managing blood pressure; they achieve this by blocking angiotensin II, a hormone responsible for narrowing blood vessels and raising fluid retention, which in turn encourages vessel widening and decreases blood pressure. As an illustration, data from October 2024, released by the Australian Bureau of Statistics, an Australia-based government entity, indicated that 11.6% (3.0 million) of Australians experienced hypertension in 2022, with comparable figures for men (11.7%) and women (11.6%). Consequently, the growing occurrence of hypertension is propelling the expansion of the renin-angiotensin system (RAS)-acting agents market.

Which Segmentation Factors Are Most Significant In The Biguanides Market Analysis?

The renin-angiotensin-system (ras)-acting agents market covered in this report is segmented –

1) By Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Renin Inhibitors, Aldosterone Antagonists, Other Drug Classes

2) By Indication: Hypertension, Heart Failure, Chronic Kidney Disease, Diabetic Nephropathy, Coronary Artery Disease

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics

4) By End-User: Hospitals, Research Institutes, Pharmaceutical Companies, Other End-Users

Subsegments:

1) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Captopril, Enalapril, Lisinopril, Ramipril, Perindopril

2) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan, Olmesartan, Telmisartan

3) By Renin Inhibitors: Aliskiren

4) By Aldosterone Antagonists: Spironolactone, Eplerenone

5) By Other Drug Classes: Dual Angiotensin Receptor-Neprilysin Inhibitors (ARNIs), Endothelin Receptor Antagonists, Vasopeptidase Inhibitors, Mineralocorticoid Receptor Antagonists (MRAs), Angiotensin Receptor Blockers With Neprilysin Inhibitors (ARNBIs)

What New Opportunities Are Emerging From Trends In The Biguanides Market?

Leading companies within the renin-angiotensin system (RAS)-acting agents market are prioritizing the creation of innovative renin-angiotensin system (RAS) inhibitors, including angiotensin-converting enzyme (ACE) inhibitors. Their aim is to boost effectiveness, mitigate adverse reactions, enhance patient adherence, and treat hypertension, heart failure, and kidney diseases. An angiotensin-converting enzyme (ACE) inhibitor operates as a drug that reduces blood pressure by inhibiting the enzyme responsible for transforming angiotensin I into angiotensin II, a compound known for constricting blood vessels. A notable example occurred in November 2023, when Proveca Ltd., a UK-based pharmaceutical company, obtained a grant from the European Commission. This grant was for pediatric use marketing authorization (PUMA) concerning Aqumeldi (enalapril maleate) orodispersible tablets, which are prescribed for managing heart failure in children from birth to less than 18 years. Aqumeldi, which functions as an angiotensin-converting enzyme (ACE) inhibitor, addresses pediatric heart failure by obstructing the angiotensin-converting enzyme (ACE), thus halting the conversion of angiotensin I to angiotensin II. This mechanism leads to the relaxation of blood vessels, improved blood flow, and a reduced burden on the heart.

Who Are The Most Influential Companies In The Biguanides Market?

Major companies operating in the renin-angiotensin-system (RAS)-acting agents market are Pfizer Inc., Merck And Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Sandoz International GmbH, Astellas Pharma Inc., Bausch Health Companies Inc., Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Biocon Limited, Daiichi Sankyo Company Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/renin-angiotensin-system-ras-acting-agents-global-market-report

Which Region Holds The Largest Share In The Biguanides Market Today?

North America was the largest region in the renin-angiotensin-system (RAS)-acting agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the renin-angiotensin-system (RAS)-acting agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=23496&type=smp

Browse Through More Reports Similar to the Global Biguanides Market 2025, By The Business Research Company

Blood And Blood Components Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-and-blood-components-global-market-report

Blood Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Wearable Blood Pressure Monitors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/wearable-blood-pressure-monitors-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Growth Projections For The Renin-Angiotensin-System (RAS)-Acting Agents Market Size During 2025–2029?

The market size for renin-angiotensin-system (RAS)-acting agents has experienced consistent growth over recent years. This market is projected to expand from $5.82 billion in 2024 to $6.11 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 5.0%. Historically, this expansion has been driven by factors such as the rising occurrence of hypertension, the increasing frequency of cardiovascular diseases, an expanding aging demographic, heightened public awareness regarding blood pressure control, robust support from clinical research, and the successful regulatory approval of new medications.

The market for renin-angiotensin-system (RAS)-acting agents is projected to experience robust expansion over the coming years. This market is forecast to reach $7.55 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 5.4%. This projected growth during the forecast period is fueled by several factors, including an increased emphasis on personalized treatment, a surge in demand for fixed-dose drug combinations, greater investment in cardiovascular research, improved healthcare accessibility in developing economies, and the escalating incidence of lifestyle-associated illnesses. Key developments anticipated within this timeframe encompass artificial intelligence (AI)-powered drug development, drug delivery utilizing nanotechnology, strides in personalized medicine, the application of blockchain for securing clinical data, the use of wearable biosensors for blood pressure monitoring, and the implementation of digital twin technology for modeling patient scenarios.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23496&type=smp

What Are The Drivers Pushing New Developments In The Renin-Angiotensin-System (RAS)-Acting Agents Market?

The rising occurrence of hypertension is anticipated to boost the expansion of the renin-angiotensin system (RAS)-acting agents market. Hypertension, also known as elevated blood pressure, is a persistent medical state characterized by excessively high blood pressure against arterial walls. The increase in hypertension cases stems from poor dietary habits, specifically those rich in sodium and processed items, which lead to higher blood pressure and stress on the heart and blood vessels. Renin-angiotensin system (RAS)-acting agents aid in decreasing hypertension rates by managing blood pressure; they achieve this by blocking angiotensin II, a hormone that narrows blood vessels and causes fluid buildup, thus encouraging vessel widening and reducing blood pressure. As an illustration, data from October 2024 by the Australian Bureau of Statistics, an Australia-based government agency, indicated that 11.6% (3.0 million) of Australians suffered from hypertension in 2022, with comparable figures for males (11.7%) and females (11.6%). Consequently, the growing incidence of hypertension is fueling the growth of the renin-angiotensin system (RAS)-acting agents market.

Which Key Segments Fueling The Renin-Angiotensin-System (RAS)-Acting Agents Market?

The renin-angiotensin-system (ras)-acting agents market covered in this report is segmented –

1) By Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Renin Inhibitors, Aldosterone Antagonists, Other Drug Classes

2) By Indication: Hypertension, Heart Failure, Chronic Kidney Disease, Diabetic Nephropathy, Coronary Artery Disease

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics

4) By End-User: Hospitals, Research Institutes, Pharmaceutical Companies, Other End-Users

Subsegments:

1) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Captopril, Enalapril, Lisinopril, Ramipril, Perindopril

2) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan, Olmesartan, Telmisartan

3) By Renin Inhibitors: Aliskiren

4) By Aldosterone Antagonists: Spironolactone, Eplerenone

5) By Other Drug Classes: Dual Angiotensin Receptor-Neprilysin Inhibitors (ARNIs), Endothelin Receptor Antagonists, Vasopeptidase Inhibitors, Mineralocorticoid Receptor Antagonists (MRAs), Angiotensin Receptor Blockers With Neprilysin Inhibitors (ARNBIs)

Which Ongoing Trends Are Expected To Shape The Renin-Angiotensin-System (RAS)-Acting Agents Market Outlook?

Leading companies in the renin-angiotensin system (RAS)-acting agents market are concentrating on developing innovative renin-angiotensin system (RAS) inhibitors, such as angiotensin-converting enzyme (ACE) inhibitors. This focus aims to boost efficacy, minimize adverse effects, enhance patient adherence, and address conditions including hypertension, heart failure, and kidney diseases. An angiotensin-converting enzyme (ACE) inhibitor is a medication that effectively lowers blood pressure by inhibiting the enzyme responsible for converting angiotensin I to angiotensin II, a substance known to constrict blood vessels. As an example, in November 2023, Proveca Ltd., a UK-based pharmaceutical company, was awarded a grant by the European Commission for pediatric use marketing authorization (PUMA) for Aqumeldi (enalapril maleate) orodispersible tablets. These tablets are indicated for treating heart failure in children from birth to less than 18 years. Aqumeldi, an angiotensin-converting enzyme (ACE) inhibitor, works to treat pediatric heart failure patients by blocking the angiotensin-converting enzyme (ACE). This prevents the conversion of angiotensin I to angiotensin II, consequently relaxing blood vessels, improving blood flow, and lessening the heart’s workload.

Which Major Industry Participants Are Leading The Renin-Angiotensin-System (RAS)-Acting Agents Market Growth?

Major companies operating in the renin-angiotensin-system (RAS)-acting agents market are Pfizer Inc., Merck And Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Sandoz International GmbH, Astellas Pharma Inc., Bausch Health Companies Inc., Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Biocon Limited, Daiichi Sankyo Company Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/renin-angiotensin-system-ras-acting-agents-global-market-report

What Are The Key Regional Factors Influencing The Renin-Angiotensin-System (RAS)-Acting Agents Market Growth?

North America was the largest region in the renin-angiotensin-system (RAS)-acting agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the renin-angiotensin-system (RAS)-acting agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Renin-Angiotensin-System (RAS)-Acting Agents Market Report:

https://www.thebusinessresearchcompany.com/customise?id=23496&type=smp

Browse Through More Reports Similar to the Global Renin-Angiotensin-System (RAS)-Acting Agents Market 2025, By The Business Research Company

Blood And Blood Components Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-and-blood-components-global-market-report

Blood Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Wearable Blood Pressure Monitors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/wearable-blood-pressure-monitors-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Much Will The Renin-Angiotensin-System (RAS)-Acting Agents Market Be Worth By 2029?

The market for agents that act on the renin-angiotensin-system (RAS) has witnessed consistent expansion in the recent past. Projections for growth indicate an increase from $5.82 billion in 2024 to $6.11 billion in 2025, with a compound annual growth rate (CAGR) of 5.0%. Several factors have spurred growth during the historic period, including a higher prevalence of hypertension, a rise in cardiovascular disease cases, an aging population, enhanced awareness about managing blood pressure, substantial support from clinical research, and approval of new drugs by regulatory bodies.

The market for agents targeting the renin-angiotensin-system (RAS) is forecasted to experience significant growth in the coming years, reaching a value of $7.55 billion by 2029, with a compound annual growth rate (CAGR) of 5.4%. Factors contributing to the projected growth include the increasing emphasis on individualized treatment strategies, amplified demand for fixed-dose combination therapy, escalated funding for cardiovascular research, enhanced health service accessibility in developing markets, and a rising incidence of lifestyle-associated diseases. Trends predicted to drive the market within this forecast timeframe involve the use of artificial intelligence in drug development, the incorporation of nanotechnology in drug delivery systems, advances in personalized medicine, using blockchain for the secure transfer of clinical data, the application of wearable biosensors for tracking hypertension, and the use of digital twin technology for creating patient models.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23496&type=smp

What External And Internal Drivers Are Influencing The Renin-Angiotensin-System (RAS)-Acting Agents Market?

The growth of the renin-angiotensin system (RAS)-acting agents market is anticipated to surge due to the amplified cases of hypertension. Hypertension, also known as high blood pressure, is a long-term health issue characterised by a persistently high force of blood applied to the artery walls. Factors such as unhealthy eating habits, especially the consumption of salt and processed foods, are contributing to the spike in hypertension cases, leading to an increased burden on the cardiovascular system. RAS-acting agents serve to mitigate the prevalence of hypertension by controlling blood pressure. This is achieved by inhibiting angiotensin II, a hormone that narrows blood vessels and promotes fluid retention, thereby facilitating vasodilation and decreasing blood pressure. As an example, the Australian Bureau of Statistics, a government agency in Australia, reported in October 2024 that 11.6% (3.0 million) of Australians suffered from hypertension in 2022, with the rates equally distributed among males (11.7%) and females (11.6%). Hence, the rising cases of hypertension provide impetus for the expansion of the renin-angiotensin system (RAS)-acting agents market.

How Is The Renin-Angiotensin-System (RAS)-Acting Agents Market Categorized Across Applications And Types?

The renin-angiotensin-system (ras)-acting agents market covered in this report is segmented –

1) By Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Renin Inhibitors, Aldosterone Antagonists, Other Drug Classes

2) By Indication: Hypertension, Heart Failure, Chronic Kidney Disease, Diabetic Nephropathy, Coronary Artery Disease

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics

4) By End-User: Hospitals, Research Institutes, Pharmaceutical Companies, Other End-Users

Subsegments:

1) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Captopril, Enalapril, Lisinopril, Ramipril, Perindopril

2) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan, Olmesartan, Telmisartan

3) By Renin Inhibitors: Aliskiren

4) By Aldosterone Antagonists: Spironolactone, Eplerenone

5) By Other Drug Classes: Dual Angiotensin Receptor-Neprilysin Inhibitors (ARNIs), Endothelin Receptor Antagonists, Vasopeptidase Inhibitors, Mineralocorticoid Receptor Antagonists (MRAs), Angiotensin Receptor Blockers With Neprilysin Inhibitors (ARNBIs)

How Are Market Trends Influencing Competition In The Renin-Angiotensin-System (RAS)-Acting Agents Market?

Leading firms in the market for renin-angiotensin system (RAS)-acting agents are dedicating their effort in the creation of advanced renin-angiotensin system (RAS) inhibitors, such as angiotensin-converting enzyme (ACE) inhibitors, in a bid to maximize effectiveness, reduce adverse reactions, boost patient adherence, and cater to conditions such as high blood pressure, heart failure, and renal diseases. An angiotensin-converting enzyme (ACE) inhibitor is a drug that suppresses blood pressure by impeding the enzyme that transforms angiotensin I into angiotensin II, a compound that tightens blood vessels. To demonstrate, in November 2023, Proveca Ltd. a pharmaceutical firm from the UK, was awarded a grant by the European Commission for pediatric use marketing authorization (PUMA) for Aqumeldi (enalapril maleate) orodispersible tablets, which are intended for addressing heart failure in children from birth up to 18 years of age. Aqumeldi is an angiotensin-converting enzyme (ACE) inhibitor that eases the conditions of pediatric heart failure patients by inhibiting the angiotensin-converting enzyme (ACE), blocking the transformation of angiotensin I into angiotensin II, consequently dilating blood vessels, enhancing blood circulation, and reducing heart strain.

Who Are The Most Influential Companies In The Renin-Angiotensin-System (RAS)-Acting Agents Market?

Major companies operating in the renin-angiotensin-system (RAS)-acting agents market are Pfizer Inc., Merck And Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Sandoz International GmbH, Astellas Pharma Inc., Bausch Health Companies Inc., Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Biocon Limited, Daiichi Sankyo Company Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/renin-angiotensin-system-ras-acting-agents-global-market-report

Which Region Holds The Greatest Opportunity For Renin-Angiotensin-System (RAS)-Acting Agents Market Expansion?

North America was the largest region in the renin-angiotensin-system (RAS)-acting agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the renin-angiotensin-system (RAS)-acting agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=23496&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Key Milestones in the Renin-Angiotensin-System (RAS)-Acting Agents Market’s Growth Trajectory From 2025 To 2034?

The market for agents acting on the renin-angiotensin-system (RAS) has witnessed consistent growth over the past few years. Its size is projected to increase from $5.82 billion in 2024 to $6.11 billion in 2025, registering a compound annual growth rate (CAGR) of 5.0%. The growth witnessed during the historical period can be explained by a rise in hypertension cases, an increase in cardiovascular diseases, the steadily growing aged population, heightened awareness regarding blood pressure regulation, robust backing from clinical research, and regulatory clearance for fresh medications.

The market size of agents acting on the renin-angiotensin-system (RAS) is predicted to witness robust growth in the coming years, propelling it to a value of $7.55 billion in 2029 at a compound annual growth rate (CAGR) of 5.4%. The increasing concentration on customised treatments, a surge in the demand for fixed-dose combinations, raising funds towards cardiovascular research, broadening access to healthcare in emerging markets, and the rising prevalence of diseases tied to lifestyle factors are all contributors to the forecasted growth. During the forecasted period, key trends expected to emerge include drug development powered by artificial intelligence (AI), nanotechnology-driven drug delivery systems, advancements in personalized medicine, the use of blockchain for safeguarding clinical data, hypertension monitoring through wearable biosensors, and the application of digital twin technology for modelling patients.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23496&type=smp

What External and Internal Drivers Are Contributing to the Growth of theRenin-Angiotensin-System (RAS)-Acting Agents Market?

The rising occurrence of hypertension is anticipated to stimulate the development of the renin-angiotensin system (RAS)-acting agents market. Hypertension is a long-term health condition characterized by continuously elevated blood pressure against the arterial walls. The surge in hypertension cases can be attributed to poor nutrition habits, particularly excessive salt and processed food intake that leads to increased blood pressure and puts pressure on the heart. The RAS-acting agents help in the control of hypertension by regulating blood pressure through the suppression of angiotensin II, a hormone that narrows blood vessels and increases fluid retention, leading to vasodilation and decreased blood pressure. For example, data from the Australian Bureau of Statistics in October 2024 indicated that in 2022, 11.6% (3.0 million) of Australians suffered from hypertension, with comparable rates in males (11.7%) and females (11.6%). Hence, the growing occurrence of hypertension is fuelling the expansion of the renin-angiotensin system (RAS)-acting agents market.

What Segment Types Define the Renin-Angiotensin-System (RAS)-Acting Agents Market Structure?

The renin-angiotensin-system (ras)-acting agents market covered in this report is segmented –

1) By Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Renin Inhibitors, Aldosterone Antagonists, Other Drug Classes

2) By Indication: Hypertension, Heart Failure, Chronic Kidney Disease, Diabetic Nephropathy, Coronary Artery Disease

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics

4) By End-User: Hospitals, Research Institutes, Pharmaceutical Companies, Other End-Users

Subsegments:

1) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Captopril, Enalapril, Lisinopril, Ramipril, Perindopril

2) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan, Olmesartan, Telmisartan

3) By Renin Inhibitors: Aliskiren

4) By Aldosterone Antagonists: Spironolactone, Eplerenone

5) By Other Drug Classes: Dual Angiotensin Receptor-Neprilysin Inhibitors (ARNIs), Endothelin Receptor Antagonists, Vasopeptidase Inhibitors, Mineralocorticoid Receptor Antagonists (MRAs), Angiotensin Receptor Blockers With Neprilysin Inhibitors (ARNBIs)

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=23496&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Renin-Angiotensin-System (RAS)-Acting Agents Market?

North America was the largest region in the renin-angiotensin-system (RAS)-acting agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the renin-angiotensin-system (RAS)-acting agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Long-Term Trends Are Transforming the Competitive Landscape of the Renin-Angiotensin-System (RAS)-Acting Agents Market?

Leading firms in the renin-angiotensin system (RAS) agents market are prioritizing the creation of unique RAS blockers, such as angiotensin-converting enzyme (ACE) inhibitors. These efforts aim to boost efficacy, curtail adverse reactions, enhance patient adherence, and address health conditions like hypertension, cardiac failure, and renal diseases. An ACE inhibitor acts as a medication that reduces blood pressure by inhibiting the enzyme responsible for converting angiotensin I into angiotensin II, a compound that constricts blood vessels. In November of 2023, Proveca Ltd., a pharmaceutical organization based in the UK, was awarded a grant by the European Commission for pediatric use marketing authorization (PUMA) for its product, Aqumeldi (enalapril maleate) orodispersible tablets. These tablets, intended for infants to individuals under 18 years, are used for heart failure treatment. Aqumeldi, an ACE inhibitor, benefits children suffering from cardiac failure by obstructing the angiotensin-converting enzyme (ACE), thereby preventing the changing of angiotensin I into angiotensin II. This process aids in blood vessel dilation, improved blood circulation, and reduced heart stress.

View the full report here:

https://www.thebusinessresearchcompany.com/report/renin-angiotensin-system-ras-acting-agents-global-market-report

What Is the Definition of the Renin-Angiotensin-System (RAS)-Acting Agents Market?

The renin-angiotensin system (RAS)-acting agents are a class of medications that regulate blood pressure, fluid balance, and vascular resistance by targeting various components of the renin-angiotensin system, which plays a crucial role in cardiovascular and renal function. These agents are commonly prescribed to treat conditions like hypertension, heart failure, and chronic kidney disease by either blocking the production of angiotensin II or inhibiting its effects on blood vessels.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23496

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Renin-Angiotensin-System (RAS)-Acting Agents Market Growth in 2025?

In recent times, there has been a robust growth in the market size of the renin-angiotensin-system (RAS)-acting agents. It is projected to climb from $5.82 billion in 2024 to $6.17 billion in 2025, securing a compound annual growth rate (CAGR) of 6.0%. The growth during the former period can be credited to factors such as the escalating prevalence of hypertension, growth in cardiovascular disease cases, the rise in elderly population, increased cognizance regarding blood pressure management, substantial clinical research backing, and the granting of regulatory approvals for new drugs.

What Is the Forecast for the Renin-Angiotensin-System (RAS)-Acting Agents Market Size Through 2029?

The market for renin-angiotensin-system (RAS)-acting agents is projected to experience substantial growth in the coming years, increasing to $7.73 billion in 2029 with a compound annual growth rate (CAGR) of 5.8%. This anticipated growth during the forecast period is due to factors such as an increasing emphasis on customized therapies, growing demand for fixed-dose combinations, heightened investment in cardiovascular study, expanding healthcare availability in developing markets, and the rising occurrence of diseases related to lifestyle. Noteworthy developments expected in the forecast period include drug development driven by artificial intelligence (AI), nanotechnology-assisted drug delivery, advancements in personalized medicine, application of blockchain for secure clinical data storage, wearable biosensors for monitoring hypertension, and the use of digital twin technology in patient simulation.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23496&type=smp

What are the Key Market Players in Renin-Angiotensin-System (RAS)-Acting Agents Market and How They’re Evolving?

Major companies operating in the renin-angiotensin-system (RAS)-acting agents market are Pfizer Inc., Merck And Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Sandoz International GmbH, Astellas Pharma Inc., Bausch Health Companies Inc., Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Biocon Limited, Daiichi Sankyo Company Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd.

What Are the Primary Growth Drivers in the Renin-Angiotensin-System (RAS)-Acting Agents Market?

Expected growth in the renin-angiotensin system (RAS)-acting agents market is believed to be driven by the escalating occurrence of hypertension. Hypertension, also known as high blood pressure, is a chronic health issue where the blood pressure against the artery walls is persistently too high. The spike in hypertension is attributed to unhealthy eating habits, especially diets rich in salt and processed foods leading to heightened blood pressure and stress on the cardiovascular system. Renin-angiotensin system (RAS)-acting agents assist in controlling hypertension by managing blood pressure. They work by curbing angiotensin II, a hormone that tightens blood vessels and boosts fluid retention, thereby facilitating vasodilation and reducing blood pressure. As evidence, as of October 2024, the Australian Bureau of Statistics, a government agency in Australia, reported that 11.6% (3.0 million) of Australians were diagnosed with hypertension in 2022, with similar figures for both men (11.7%) and women (11.6%). For these reasons, the escalating prevalence of hypertension is contributing to the expansion of the renin-angiotensin system (RAS)-acting agents market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=23496&type=smp

What Are the Leading Segments in the Global Renin-Angiotensin-System (RAS)-Acting Agents Industry?

The renin-angiotensin-system (RAS)-acting agents market covered in this report is segmented –

1) By Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Renin Inhibitors, Aldosterone Antagonists, Other Drug Classes

2) By Indication: Hypertension, Heart Failure, Chronic Kidney Disease, Diabetic Nephropathy, Coronary Artery Disease

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics

4) By End-User: Hospitals, Research Institutes, Pharmaceutical Companies, Other End-Users

Subsegments:

1) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Captopril, Enalapril, Lisinopril, Ramipril, Perindopril

2) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan, Olmesartan, Telmisartan

3) By Renin Inhibitors: Aliskiren

4) By Aldosterone Antagonists: Spironolactone, Eplerenone

5) By Other Drug Classes: Dual Angiotensin Receptor-Neprilysin Inhibitors (ARNIs), Endothelin Receptor Antagonists, Vasopeptidase Inhibitors, Mineralocorticoid Receptor Antagonists (MRAs), Angiotensin Receptor Blockers With Neprilysin Inhibitors (ARNBIs)

What Are the Key Market Trends in the Renin-Angiotensin-System (RAS)-Acting Agents Industry?

Primary businesses in the market for renin-angiotensin system (RAS)-acting agents are concentrating their efforts on the creation of new renin-angiotensin system (RAS) blockers, including angiotensin-converting enzyme (ACE) inhibitors. The aim is to maximize effectiveness, decrease adverse reactions, enhance patient adherence, and address conditions like hypertension, heart failure, and kidney disease. ACE inhibitors are medications that manipulate blood pressure and inhibit the enzyme responsible for converting angiotensin I into angiotensin II, a substance that constricts blood vessels. For example, in November 2023, UK pharmaceutical company Proveca Ltd. was granted a pediatric use marketing authorization (PUMA) by the European Commission for Aqumeldi (enalapril maleate) oro-dispersible tablets, which are meant for the treatment of heart failure in children aged newborn to under 18. By blocking the ACE and halting the conversion from angiotensin I to angiotensin II, Aqumeldi relaxes the blood vessels, enhances blood circulation, and reduces the heart’s workload in treatment of pediatric heart failure.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/renin-angiotensin-system-ras-acting-agents-global-market-report

What Is the Regional Outlook for the Renin-Angiotensin-System (RAS)-Acting Agents Market?

North America was the largest region in the renin-angiotensin-system (RAS)-acting agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the renin-angiotensin-system (RAS)-acting agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23496

This Report Delivers Insight On:

1. How big is the renin-angiotensin-system (ras)-acting agents market, and how is it changing globally?

2. Who are the major companies in the renin-angiotensin-system (ras)-acting agents market, and how are they performing?

3. What are the key opportunities and risks in the renin-angiotensin-system (ras)-acting agents market right now?

4. Which products or customer segments are growing the most in the renin-angiotensin-system (ras)-acting agents market?

5. What factors are helping or slowing down the growth of the renin-angiotensin-system (ras)-acting agents market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Renin-Angiotensin-System (RAS)-Acting Agents Market Growth in 2025?

In recent times, there has been a robust growth in the market size of the renin-angiotensin-system (RAS)-acting agents. It is projected to climb from $5.82 billion in 2024 to $6.17 billion in 2025, securing a compound annual growth rate (CAGR) of 6.0%. The growth during the former period can be credited to factors such as the escalating prevalence of hypertension, growth in cardiovascular disease cases, the rise in elderly population, increased cognizance regarding blood pressure management, substantial clinical research backing, and the granting of regulatory approvals for new drugs.

What Is the Forecast for the Renin-Angiotensin-System (RAS)-Acting Agents Market Size Through 2029?

The market for renin-angiotensin-system (RAS)-acting agents is projected to experience substantial growth in the coming years, increasing to $7.73 billion in 2029 with a compound annual growth rate (CAGR) of 5.8%. This anticipated growth during the forecast period is due to factors such as an increasing emphasis on customized therapies, growing demand for fixed-dose combinations, heightened investment in cardiovascular study, expanding healthcare availability in developing markets, and the rising occurrence of diseases related to lifestyle. Noteworthy developments expected in the forecast period include drug development driven by artificial intelligence (AI), nanotechnology-assisted drug delivery, advancements in personalized medicine, application of blockchain for secure clinical data storage, wearable biosensors for monitoring hypertension, and the use of digital twin technology in patient simulation.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23496&type=smp

What are the Key Market Players in Renin-Angiotensin-System (RAS)-Acting Agents Market and How They’re Evolving?

Major companies operating in the renin-angiotensin-system (RAS)-acting agents market are Pfizer Inc., Merck And Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Sandoz International GmbH, Astellas Pharma Inc., Bausch Health Companies Inc., Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Biocon Limited, Daiichi Sankyo Company Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd.

What Are the Primary Growth Drivers in the Renin-Angiotensin-System (RAS)-Acting Agents Market?

Expected growth in the renin-angiotensin system (RAS)-acting agents market is believed to be driven by the escalating occurrence of hypertension. Hypertension, also known as high blood pressure, is a chronic health issue where the blood pressure against the artery walls is persistently too high. The spike in hypertension is attributed to unhealthy eating habits, especially diets rich in salt and processed foods leading to heightened blood pressure and stress on the cardiovascular system. Renin-angiotensin system (RAS)-acting agents assist in controlling hypertension by managing blood pressure. They work by curbing angiotensin II, a hormone that tightens blood vessels and boosts fluid retention, thereby facilitating vasodilation and reducing blood pressure. As evidence, as of October 2024, the Australian Bureau of Statistics, a government agency in Australia, reported that 11.6% (3.0 million) of Australians were diagnosed with hypertension in 2022, with similar figures for both men (11.7%) and women (11.6%). For these reasons, the escalating prevalence of hypertension is contributing to the expansion of the renin-angiotensin system (RAS)-acting agents market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=23496&type=smp

What Are the Leading Segments in the Global Renin-Angiotensin-System (RAS)-Acting Agents Industry?

The renin-angiotensin-system (RAS)-acting agents market covered in this report is segmented –

1) By Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Renin Inhibitors, Aldosterone Antagonists, Other Drug Classes

2) By Indication: Hypertension, Heart Failure, Chronic Kidney Disease, Diabetic Nephropathy, Coronary Artery Disease

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics

4) By End-User: Hospitals, Research Institutes, Pharmaceutical Companies, Other End-Users

Subsegments:

1) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Captopril, Enalapril, Lisinopril, Ramipril, Perindopril

2) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan, Olmesartan, Telmisartan

3) By Renin Inhibitors: Aliskiren

4) By Aldosterone Antagonists: Spironolactone, Eplerenone

5) By Other Drug Classes: Dual Angiotensin Receptor-Neprilysin Inhibitors (ARNIs), Endothelin Receptor Antagonists, Vasopeptidase Inhibitors, Mineralocorticoid Receptor Antagonists (MRAs), Angiotensin Receptor Blockers With Neprilysin Inhibitors (ARNBIs)

What Are the Key Market Trends in the Renin-Angiotensin-System (RAS)-Acting Agents Industry?

Primary businesses in the market for renin-angiotensin system (RAS)-acting agents are concentrating their efforts on the creation of new renin-angiotensin system (RAS) blockers, including angiotensin-converting enzyme (ACE) inhibitors. The aim is to maximize effectiveness, decrease adverse reactions, enhance patient adherence, and address conditions like hypertension, heart failure, and kidney disease. ACE inhibitors are medications that manipulate blood pressure and inhibit the enzyme responsible for converting angiotensin I into angiotensin II, a substance that constricts blood vessels. For example, in November 2023, UK pharmaceutical company Proveca Ltd. was granted a pediatric use marketing authorization (PUMA) by the European Commission for Aqumeldi (enalapril maleate) oro-dispersible tablets, which are meant for the treatment of heart failure in children aged newborn to under 18. By blocking the ACE and halting the conversion from angiotensin I to angiotensin II, Aqumeldi relaxes the blood vessels, enhances blood circulation, and reduces the heart’s workload in treatment of pediatric heart failure.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/renin-angiotensin-system-ras-acting-agents-global-market-report

What Is the Regional Outlook for the Renin-Angiotensin-System (RAS)-Acting Agents Market?

North America was the largest region in the renin-angiotensin-system (RAS)-acting agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the renin-angiotensin-system (RAS)-acting agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23496

This Report Delivers Insight On:

1. How big is the renin-angiotensin-system (ras)-acting agents market, and how is it changing globally?

2. Who are the major companies in the renin-angiotensin-system (ras)-acting agents market, and how are they performing?

3. What are the key opportunities and risks in the renin-angiotensin-system (ras)-acting agents market right now?

4. Which products or customer segments are growing the most in the renin-angiotensin-system (ras)-acting agents market?

5. What factors are helping or slowing down the growth of the renin-angiotensin-system (ras)-acting agents market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Get 30% off on our Global Market Reports with code ONLINE30 – Hurry, limited time offer!

How Has The Renin-Angiotensin-System (RAS)-Acting Agents Market Growth Evolved From 2024 To 2025, And What’s Ahead?

In recent times, the market size of renin-angiotensin-system (RAS)-acting agents has seen substantial growth. It’s forecasted to escalate from $5.82 billion in 2024 to $6.17 billion in 2025, with a compound annual growth rate (CAGR) of 6.0%. This growth over the historical period is linked to various factors such as the rising cases of hypertension, growing incidences of cardiovascular diseases, an increase in the aging population, greater consciousness regarding the management of blood pressure, robust support from clinical research, and the approval of new drugs by regulatory bodies.

The market for agents that act on the renin-angiotensin system (RAS) is predicted to experience substantial growth in the upcoming years. Its value is projected to hit $7.73 billion by 2029, with an expected compound annual growth rate (CAGR) of 5.8%. This projected surge over the forecast period can be credited to several factors such as an increased emphasis on personalized treatment, soaring demand for fixed-dose combinations, escalated investment in cardiovascular studies, expanding access to healthcare in emerging economies, and a growing incidence of diseases tied to lifestyle choices. Key trends expected to shape this market during the forecast period include the application of artificial intelligence (AI) in drug discovery, delivery of drugs using nanotechnology, advancements in personalized medicine, using blockchain for secure clinical data sharing, hypertension monitoring through wearable biosensors, and employing digital twin technology for patient simulation.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23496&type=smp

What Are the Major Market Drivers Behind the Rising Adoption of Renin-Angiotensin-System (RAS)-Acting Agents Market?

The escalating occurrence of hypertension is projected to stimulate the expansion of the renin-angiotensin system (RAS)-acting agents market in the future. Hypertension, also known as high blood pressure, signifies a continuous health situation where the pressure against the arterial walls remains excessively high. This occurrence happens primarily due to unhealthy eating habits, especially those involving high salt and processed food consumption that lead to blood pressure surge and cardiovascular system strain. RAS-acting agents play a crucial role in curbing hypertension incidence by controlling blood pressure through the restriction of angiotensin II, a hormone responsible for blood vessel constriction and fluid retention, which in effect facilitates vasodilation and a consequent decrease in blood pressure. For example, in October 2024, data from the Australian Bureau of Statistics, an Australia-based governmental organization, showed that 11.6% (3.0 million) of Australians were experiencing hypertension in 2022, with virtually equal rates of occurrence in males (11.7%) and females (11.6%). Therefore, the escalating occurrence of hypertension is the key factor boosting the growth of the renin-angiotensin system (RAS)-acting agents market.

Which Key Market Segments Comprise the Renin-Angiotensin-System (RAS)-Acting Agents Market and Drive Its Revenue Growth?

The renin-angiotensin-system (RAS)-acting agents market covered in this report is segmented –

1) By Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Renin Inhibitors, Aldosterone Antagonists, Other Drug Classes

2) By Indication: Hypertension, Heart Failure, Chronic Kidney Disease, Diabetic Nephropathy, Coronary Artery Disease

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics

4) By End-User: Hospitals, Research Institutes, Pharmaceutical Companies, Other End-Users

Subsegments:

1) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Captopril, Enalapril, Lisinopril, Ramipril, Perindopril

2) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan, Olmesartan, Telmisartan

3) By Renin Inhibitors: Aliskiren

4) By Aldosterone Antagonists: Spironolactone, Eplerenone

5) By Other Drug Classes: Dual Angiotensin Receptor-Neprilysin Inhibitors (ARNIs), Endothelin Receptor Antagonists, Vasopeptidase Inhibitors, Mineralocorticoid Receptor Antagonists (MRAs), Angiotensin Receptor Blockers With Neprilysin Inhibitors (ARNBIs)

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=23496&type=smp

Which Areas Are Leading Regions in the Renin-Angiotensin-System (RAS)-Acting Agents Market Expansion Across the Globe?

North America was the largest region in the renin-angiotensin-system (RAS)-acting agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the renin-angiotensin-system (RAS)-acting agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Strategic Trends Steering the Renin-Angiotensin-System (RAS)-Acting Agents Market Direction?

Leading players in the renin-angiotensin system (RAS)-acting agents market are directing their efforts towards the creation of innovative renin-angiotensin system (RAS) inhibitors, such as angiotensin-converting enzyme (ACE) inhibitors. This development is geared towards increasing effectiveness, reducing adverse effects, enhancing patient adherence, and targeting conditions such as hypertension, heart failure, and kidney diseases. ACE inhibitors are drugs that lower blood pressure by preventing the enzyme that transforms angiotensin I into angiotensin II, a compound that constricts blood vessels. For example, Proveca Ltd., a pharmaceutical firm based in the UK, received a grant from the European Commission for pediatric use marketing authorization (PUMA) in November 2023. This grant was for Aqumeldi (enalapril maleate) orodispersible tablets, designed to treat heart failure in children ranging from newborns to those under 18 years. Aqumeldi, an ACE inhibitor, aids child heart failure patients by inhibiting the ACE, blocking the transformation of angiotensin I into angiotensin II, hence broadening blood vessels, improving blood circulation, and lessening the heart’s burden.

View the full report here:

https://www.thebusinessresearchcompany.com/report/renin-angiotensin-system-ras-acting-agents-global-market-report

How Is the Renin-Angiotensin-System (RAS)-Acting Agents Market Conceptually Defined?

The renin-angiotensin system (RAS)-acting agents are a class of medications that regulate blood pressure, fluid balance, and vascular resistance by targeting various components of the renin-angiotensin system, which plays a crucial role in cardiovascular and renal function. These agents are commonly prescribed to treat conditions like hypertension, heart failure, and chronic kidney disease by either blocking the production of angiotensin II or inhibiting its effects on blood vessels.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23496

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model